Want to see JP:4890 full AI Analyst Report?
4890 Stock Chart & Stats
¥340.00
¥1.00(0.24%)
At close: 4:00 PM EST
¥340.00
¥1.00(0.24%)
Day’s Range― - ―
52-Week Range¥210.00 - ¥478.00
Previous CloseN/A
Volume43.10K
Average Volume (3M)44.26K
Market Cap
¥6.96B
Enterprise Value¥5.27K
Total Cash (Recent Filing)¥699.26M
Total Debt (Recent Filing)¥63.64M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-26.90
Shares Outstanding25,969,738
10 Day Avg. Volume48,210
30 Day Avg. Volume44,263
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.77
Price to Sales (P/S)37.86
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage gives the company greater financial resilience while operating results fluctuate. Limited debt exposure can reduce financing pressure, preserve borrowing capacity, and leave more flexibility to support ophthalmology development or withstand continued earnings volatility.
Strong Gross MarginA gross margin near 66% indicates that the company’s offerings can retain meaningful value after direct costs. If revenue stabilizes, this underlying margin profile could support operating leverage and help restore profitability, although the current fixed-cost burden remains substantial.
Demonstrated Prior ProfitabilityEarlier profitable periods and the 2025 rebound show that the business has previously converted its ophthalmology activities into earnings. This provides evidence of potential earnings capability over time, even though the latest year demonstrates that performance is highly unstable.
Bears Say
Severe Revenue ContractionAn 85.3% revenue collapse materially weakens the company’s operating base and makes future earnings harder to predict. Such a sharp contraction can reduce the ability to absorb fixed costs, fund product development, and sustain commercial momentum over the next several quarters.
Deep Operating LossesDeep losses show that the current revenue level is insufficient to cover the company’s cost structure despite its relatively strong gross margin. Continued losses could erode equity, restrict investment capacity, and make a durable recovery dependent on a substantial improvement in demand or execution.
Persistent Cash BurnNegative operating cash flow across three consecutive years indicates that reported operations have not funded the business internally. Persistent cash burn can increase ongoing funding needs, reduce financial flexibility, and constrain the company’s ability to invest in growth while losses continue.
Tsubota Laboratory Incorporated News
4890 FAQ
What was Tsubota Laboratory Incorporated’s price range in the past 12 months?
Tsubota Laboratory Incorporated lowest stock price was ¥210.00 and its highest was ¥478.00 in the past 12 months.
What is Tsubota Laboratory Incorporated’s market cap?
Tsubota Laboratory Incorporated’s market cap is ¥6.96B.
When is Tsubota Laboratory Incorporated’s upcoming earnings report date?
Tsubota Laboratory Incorporated’s upcoming earnings report date is Nov 06, 2026 which is in 50 days.
How were Tsubota Laboratory Incorporated’s earnings last quarter?
Tsubota Laboratory Incorporated released its earnings results on Aug 12, 2026. The company reported -¥5.2 earnings per share for the quarter.
Is Tsubota Laboratory Incorporated overvalued?
According to Wall Street analysts Tsubota Laboratory Incorporated’s price is currently Overvalued.
Does Tsubota Laboratory Incorporated pay dividends?
Tsubota Laboratory Incorporated does not currently pay dividends.
What is Tsubota Laboratory Incorporated’s EPS estimate?
Tsubota Laboratory Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tsubota Laboratory Incorporated have?
Tsubota Laboratory Incorporated has 25,969,738 shares outstanding.
What happened to Tsubota Laboratory Incorporated’s price movement after its last earnings report?
Tsubota Laboratory Incorporated reported an EPS of -¥5.2 in its last earnings report. Following the earnings report the stock price went up 2.23%.
Which hedge fund is a major shareholder of Tsubota Laboratory Incorporated?
Currently, no hedge funds are holding shares in JP:4890
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tsubota Laboratory Incorporated
Operating from Tokyo, Japan since its establishment in 2012, Tsubota Laboratory Incorporated is dedicated to the research and development of pharmaceutical products and medical devices, specifically targeting the treatment of myopia, dry eyes, and presbyopia.
Technical Analysis
Sundrug Co
―
Sugi Holdings Co
―
TSURUHA Holdings
―
COSMOS Pharmaceutical Corporation
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―